Clinical reference
Vascular endothelial growth factor (VEGF) inhibitor · Recombinant humanized monoclonal anti-VEGF antibody · Neonatology, Ophthalmology, Pediatrics, Oncology
Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds VEGF and inhibits endothelial proliferation and angiogenesis. In neonates used off-label intravitreally for retinopathy of prematurity (ROP) type 1, zone I or posterior zone II. Most common dose 0.625 mg in 0.025 mL per eye; lower doses 0.031–0.312 mg used. Long-term benefits and s…